Hospital-Treated Gram-Negative Infections | Disease Landscape & Forecast | G7 | 2025
Due to the rising rates of antimicrobial resistance, antibiotics with activity against drug-resistant gram-negative pathogens are essential. Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited gram-negative infection (GNI) armamentarium. Despite the approval of novel antibiotics such as Shionogi’s Fetroja / Fetcroja, Innoviva’s Xacduro, and AbbVie / Pfizer’s Emblaveo, additional treatments with novel mechanisms of action that are effective in patients with drug-resistant infections are needed. Although the market is heavily genericized and cost-containment measures limit the commercial success of new therapies, innovative push-and-pull market approaches such as value-based pricing and de-linked drug reimbursement models continue to encourage and support antibiotics development.
QUESTIONS ANSWERED
- How large are the treatable HABP / VABP / HCAP, cSSSI / SSI, cIAI, BSI, and UTI populations, and what are the resistance rates to different classes of antibiotics across several pathogen species?
- What is the state of treatment for hospital-treated GNIs, and which clinical needs remain unfulfilled?
- How will increasing genericization during the forecast period impact the use of branded antibiotics?
- What impact will newer-to-market and emerging antibiotic therapies have on the hospital-treated GNI therapy market?
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: Country-specific interviews with thought-leading infectious disease specialists. Survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed events of GNIs by country, segmented by key infections; pathogens (E. coli, Pseudomonas, Acinetobacter, Klebsiella); and resistance types.
Forecast: 10-year, annualized, drug-level sales and patient share of key antibiotics through 2034, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and late-phase emerging therapies.
PRODUCT DESCRIPTION
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
